



Curriculum Vitae

Personal information **Irja Lutsar**

Work experience

1. Employer: University of Tartu, Faculty of Medicine, Department of Microbiology, Chair of Medical Microbiology and Virology
 - Start date: 2009
 - End date:
 - Position: Professor in Medical Microbiology and Virology
 - Activities:
 - Country: Estonia
2. Employer: University of Tartu, Faculty of Medicine, Department of Microbiology, Chair of Medical Microbiology and Virology
 - Start date: 2004
 - End date: 2009
 - Position: Professor in Medical Microbiology and Virology
 - Activities:
 - Country: Estonia
3. Employer: Pfizer Ltd., Global Research and Development
 - Start date: 2003
 - End date: 2004
 - Position: Director
 - Activities:
 - Country: United Kingdom
4. Employer: Pfizer Ltd., Global Research and Development
 - Start date: 1999
 - End date: 2003
 - Position: Clinical Project Manager
 - Activities:
 - Country: United Kingdom
5. Employer: Tartu University, Faculty of Medicine, Paediatric Department
 - Start date: 1998
 - End date: 1999
 - Position: Associated Professor in Paediatrics
 - Activities:
 - Country: Estonia
6. Employer: Southwestern Medical Center at Dallas
 - Start date: 1995
 - End date: 1998
 - Position: Fellow in paediatric infectious diseases
 - Activities:
 - Country: United States
7. Employer: Tartu University Children's Hospital
 - Start date: 1992
 - End date: 1995
 - Position: Head of Paediatric Infectious Diseases Department
 - Activities:
 - Country: Estonia
8. Employer: Tartu University Children's Hospital
 - Start date: 1982
 - End date: 1992
 - Position: Deputy Head of the Paediatric Hospital
 - Activities:
 - Country: Estonia
9. Employer: Võru Hospital
 - Start date: 1979
 - End date: 1982
 - Position: Paediatrician
 - Activities:
 - Country: Estonia
10. Employer: First Children's Hospital
 - Start date: 1978
 - End date: 1979
 - Position: Internship in paediatrics
 - Activities:
 - Country: Estonia

Education and training

1. Subject: Southwestern Medical School, Dallas
 - Start date: 1995
 - End date: 1998
 - Qualification: Research Fellow in Paediatric Infectious Diseases
 - Organisation:
 - Country: United States

2. Subject: University of Tartu
 - Start date: 1992
 - End date: 1995
 - Qualification: PhD
 - Organisation: Irja Lutsar, Doctor's Degree, 1995, (sup) Tiina Talvik, Kesknärvisüsteemi põletikulised haigused lastel (kliinilis_ epidemioloogiline iseloomustus ja kaugtulemused) (Infections of the central nervous system in children (epidemiologic, diagnostic and therapeutic aspects, long term outcome)), University of Tartu, Faculty of Medicine.
 - Country: Estonia
3. Subject: Tallinn First Children's Hospital
 - Start date: 1978
 - End date: 1979
 - Qualification: Internship in Paediatrics
 - Organisation:
 - Country: Estonia
4. Subject: University of Tartu
 - Start date: 1972
 - End date: 1978
 - Qualification: MD
 - Organisation:
 - Country: Estonia

Additional information

Publications

2020 Discovery and development of safe_in_man broad_spectrum antiviral agents. Andersen PI, Ianevski A, Lysvand H, Vitkauskienė A, Oksenyč V, Björås M, Telling K, Lutsar I, Dumpis U, Irie Y, Tenson T, Kantele A, Kainov DE. *Int J Infect Dis*. 2020 Apr;93:268-276. doi: 10.1016/j.ijid.2020.02.018. Epub 2020 Feb 17. PMID: 32081774 Free PMC article. Review. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. Lutsar I, Chazallon C, Trafojer U, de Cabre VM, Auriti C, Bertaina C, Calo Carducci FI, Canpolat FE, Esposito S, Fournier I, Hallik M, Heath PT, Ilmoja ML, Iosifidis E, Kuznetsova J, Meyer L, Metsvaht T, Mitsiakos G, Pana ZD, Mosca F, Pugni L, Roilides E, Rossi P, Sarafidis K, Sanchez L, Sharland M, Usonis V, Warris A, Aboulker JP, Giaquinto C; NeoMero Consortium. *PLoS One*. 2020 Mar 4;15(3):e0229380. doi: 10.1371/journal.pone.0229380. eCollection 2020. PMID: 32130261 Free PMC article. Clinical Trial. An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram_positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. Hill LF, Turner MA, Lutsar I, Heath PT, Hardy P, Linsell L, Jacqz_Aigrain E, Roilides E, Sharland M; NeoVanc Consortium. *Trials*. 2020 Apr 15;21(1):329. doi: 10.1186/s13063_020_4184_8. PMID: 32293527 Free PMC article. Clinical Trial. Characteristics of Extended_Spectrum Beta_Lactamase_Producing Enterobacteriaceae and Contact to Animals in Estonia. Telling K, Brauer A, Laht M, Kalmus P, Toompere K, Kisand V, Maimets M, Remm M, Tenson T, Lutsar I. *Microorganisms*. 2020 Jul 27;8(8):1130. doi: 10.3390/microorganisms8081130. PMID: 32727011 Free PMC article. Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus. Kõivumägi K, Toompere K, Soeorg H, Kallas E, Jõgeda EL, Huik K; Rotavirus Study group, Lutsar I. *Vaccine*. 2020 Mar 17;38(13):2879-2886. doi: 10.1016/j.vaccine.2020.01.098. Epub 2020 Feb 14. PMID: 32067818 Dynamics of pertussis toxin IgG after symptomatic pertussis in children and adults. Jõgi P, Soeorg H, Oona M, Kaart T, Toompere K, Maskina T, Koort I, Rätsep A, Lutsar I; Pertussis study group of Estonia. *Vaccine*. 2020 Apr 3;38(16):3196-3200. doi: 10.1016/j.vaccine.2020.02.080. Epub 2020 Mar 11. PMID: 32171577 2019 Folgori L, Lutsar I, Standing JF, Walker AS, Roilides E, Zautis TE, Jafri H, Giaquinto C, Turner MA, Sharland M. Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA_ID network view. *BMJ Open*. 2019 Dec 31;9(12):e032592. doi: 10.1136/bmjopen_2019_032592. Gastine S, Rashed AN, Hsia Y, Jackson C, Barker CIS, Mathur S, Tomlin S, Lutsar I, Bielicki J, Standing JF, Sharland M. GAPPS (Grading and Assessment of Pharmacokinetic_Pharmacodynamic Studies) a critical appraisal system for antimicrobial PKPD studies _development and application in pediatric antibiotic studies. *Expert Rev Clin Pharmacol*. 2019 Dec;12(12):1091-1098. doi: 10.1080/17512433.2019.1695600. Epub 2019 Nov 30. Review. Mesek I, Nellis G, Lass J, Metsvaht T, Varendi H, Visk H, Turner MA, Nunn AJ, Duncan J, Lutsar I. Medicines prescription patterns in European neonatal units. *Int J Clin Pharm*. 2019 Dec;41(6):1578-1591. doi: 10.1007/s11096_019_00923_2. Epub 2019 Oct 17. PubMed PMID: 31625122. Esposito S, Stefanelli P, Fry NK, Fedele G, He Q, Paterson P, Tan T, Knuf M, Rodrigo C, Weil Olivier C, Flanagan KL, Hung I, Lutsar I, Edwards K, O'Ryan M, Principi N; World Association of Infectious Diseases and Immunological Disorders (WAIID) and the Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG). Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. *Front Immunol*. 2019 Jul 3;10:1344. doi: 10.3389/fimmu.2019.01344. eCollection 2019. Soodla P, Huik K, Pauskar M, Cuyper L, Van Laethem K, Rajasaar H, Kallas E, Lepa H, Velts_Lindh A, Jõgeda EL, Lutsar I, Avi R. Stable level of HIV transmitted drug resistance in Estonia despite significant scale_up of antiretroviral therapy. *Infect Genet Evol*. 2019 Nov;75:103901. doi: 10.1016/j.meegid.2019.05.019. Huik K, Soodla P, Pauskar M, Owen SM, Luo W, Murphy G, Jõgeda EL, Kallas E, Rajasaar H, Avi R, Masciotra S, Lutsar I; CASCADE Collaboration in the EuroCoord. The concordance of the limiting antigen and the Bio_Rad avidity assays in persons from Estonia infected mainly with HIV_1 CRF06_cpx. *PLoS One*. 2019 May 24;14(5):e0217048. doi: 10.1371/journal.pone.0217048. eCollection 2019. Jacqz_Aigrain E, Leroux S, Thomson AH, Allegaert K, Capparelli EV, Biran V, Simon N, Meibohm B, Lo YL, Marques R, Peris JE, Lutsar I, Saito J, Nakamura H, van den Anker JN, Sharland M, Zhao W. Population pharmacokinetic meta_analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. *J Antimicrob Chemother*. 2019 Aug 1;74(8):2128-2138. Ianevski A, Zusinaite E, Shtaida N, Kallio_Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenyč V, Dumpis U, Vitkauskienė A, Stašaitis K, Öhrmalm C, Bondeson K, Bergqvist A, Cox RJ, Tenson T, Merits A, Kainov DE. Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010-2018. *Viruses*. 2019 Mar 1;11(3). 2018 Telling K, Laht M, Brauer A, Remm M, Kisand V, Maimets M, Tenson T, Lutsar I. Multidrug resistant *Pseudomonas aeruginosa* in Estonian hospitals. *BMC Infect Dis*. 2018 Oct 11;18(1):513. doi: 10.1186/s12879_018_3421_1. Parm Ü, Štšepetova J, Eelmäe I, Merila M, Ilmoja ML, Metsvaht T, Lutsar I, Soeorg H. Genetic relatedness of Gram_negative bacteria colonizing gut and skin of neonates and mother's own milk. *J Perinatol*. 2018 Nov;38(11):1503-1511. doi: 10.1038/s41372_018_0220_x. Soeorg H, Treumuth S, Metsvaht HK, Eelmäe I, Merila M, Ilmoja ML, Lutsar I, Metsvaht T. Higher intake of coagulase_negative staphylococci from maternal milk promotes gut colonization with mecA_negative *Staphylococcus epidermidis* in preterm neonates. *J Perinatol*. 2018 Oct;38(10):1344-1352. doi: 10.1038/s41372_018_0183_y. Epub 2018 Aug 3. Jõgeda EL, Avi R, Pauskar M, Kallas E, Karki T, Des Jarlais D, Uusküla A, Toompere K, Lutsar I, Huik K. Association of IFN λ 4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. *J Med Virol*. 2018 Nov;90(11):1779-1783. doi: 10.1002/jmv.25258. Epub 2018 Aug 16. Dyar OJ, Nathwani D, Monnet DL, Gyssens IC, Stålsby Lundborg C, Pulcini C; ESGAP Student_PREPARE Working Group. Do medical students feel prepared to prescribe antibiotics responsibly? Results from a cross_sectional survey in 29 European countries. *J Antimicrob Chemother*. 2018 Aug 1;73(8):2236-2242. Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio_Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenyč V, Björås M, Nordb SA, Dumpis U, Vitkauskienė A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D. Novel activities of safe_in_human broad_spectrum antiviral agents. *Antiviral Res*. 2018 Jun;154:174-182. doi: 10.1016/j.antiviral.2018.04.016. Epub 2018 Apr 23. Germovsek E, Lutsar I, Kipper K, Karlsson MO, Planche T, Chazallon C, Meyer L, Trafojer UMT, Metsvaht T, Fournier I, Sharland M, Heath P, Standing JF; NeoMero Consortium. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. *J Antimicrob Chemother*. 2018 Jul 1;73(7):1908-1916. Soeorg H, Metsvaht HK, Keränen EE, Eelmäe I, Merila M, Ilmoja ML, Metsvaht T, Lutsar I. Genetic Relatedness of *Staphylococcus haemolyticus* in Gut and Skin of Preterm Neonates and Breast Milk of Their Mothers. *Pediatr Infect Dis J*. 2019 Mar;38(3):308-313. Padari H, Metsvaht T,

Germovsek E, Barker CI, Kipper K, Herodes K, Standing JF, Oselin K, Tasa T, Soeorg H, Lutsar I. Pharmacokinetics of Penicillin G in Preterm and Term Neonates. *Antimicrob Agents Chemother*. 2018 Apr 26;62(5). pii: e02238.17. Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, Young J, Bucher HC, Babiker AG; CASCADE Collaboration in EuroCoord. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV_1 positive patients with well_estimated dates of seroconversion. *HIV Med*. 2018 Mar;19(3):184_194. Pansa P, Hsia Y, Bielicki J, Lutsar I, Walker AS, Sharland M, Folgori L. Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000_2016: A Systematic Review and Meta_Analysis. *Drugs*. 2018 Feb;78(2):231_244. doi: 10.1007/s40265_017_0850_x. PubMed PMID: 29218501. Jõgi P, Oona M, Kaart T, Toompere K, Maskina T, Koort I, Rätsep A, Lutsar I. Pertussis and parapertussis in children and adults with a persistent cough: an observational study. *Infection*. 2018 Feb;46(1):83_91. 2017 Veigue, Ruta; Aro, Rudolf; Metsvaht, Tuuli; Standing, Joseph F.; Lutsar, Irja; Herodes, Koit; Kipper, Karin (2017). A Highly Sensitive Method for the Simultaneous UHPLC_MS/MS Analysis of Clonidine, Morphine, Midazolam and their Metabolites in Blood Plasma Using HFIP as the Eluent Additive. *Journal of Chromatography B*, 1052, 150–157. j.chromb.2017.03.007. Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I (2017). Molecular epidemiology of *Staphylococcus epidermidis* in neonatal intensive care units. *APMIS*, 125, 63–73.10.1111/apm.12637. Soeorg, Hiie; Metsvaht, Tuuli; Eelmäe, Imbi; Metsvaht, Hanna Kadri; Treumuth, Sirl; Merila, Mirjam; Ilmoja, Mari_Liis; Lutsar, Irja (2017). Coagulase_Negative *Staphylococci* in Human Milk From Mothers of Preterm Compared With Term Neonates. *Journal of human lactation : official journal of International Lactation Consultant Association*, 33 (2), 329–340.10.1177/0890334417691505. Tasa, Tõnis; Metsvaht, Tuuli; Kalamees, Riste; Vilo, Jaak; Lutsar, Irja (2017). DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates. *Therapeutic Drug Monitoring*, 39 (6), 604–613.10.1097/FTD.0000000000000456. Jõgi P.; Oona M.; Kaart T.; Toompere K.; Maskina M.; Koort I.; Rätsep A.; Lutsar I. (2017). Pertussis and parapertussis in children and adults with a persistent cough: an observational study. *Infection*.10.1007/s15010_017_1095_z [ilmumas]. Oona, M.; Kaart, T.; Toompere, K.; Maskina, T.; Koort, I.; Rätsep, A.; Lutsar, I. (2017). Läkakõha toksiooni vastaste IgG_tüüpi antikehade tase lækakõhaga patsientide hulgas ning kolme aasta jooksul pärast haiguse põdemist. 96. Eesti Arst, 16. (Lisa 1). 2016 Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene_Ly; Karki, Tõnis; Rützel, Kristi; Talu, Ave; Abel_Ollo, Katrin; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. *PLoS one*, 11 (6), e0156850–e0156850.10.1371/journal.pone.0156850. Germovsek, Eva; Kent, Alison; Metsvaht, Tuuli; Lutsar, Irja; Klein, Nigel; Turner, Mark A; Sharland, Mike; Nielsen, Elisabet I; Heath, Paul T; Standing, Joseph F (2016). Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants. *Antimicrobial agents and chemotherapy*, 60 (8), 4869–4877.10.1128/AAC.00577_16. Folgori, Laura; Bielicki, Julia; Ruiz, Beatriz; Turner, Mark A; Bradley, John S; Benjamin, Daniel K; Zaoutis, Theoklis E; Lutsar, Irja; Giaquinto, Carlo; Rossi, Paolo; Sharland, Mike (2016). Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. *The Lancet. Infectious diseases*, 16 (9), 178–189.10.1016/S1473_3099(16)00069_4. Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Lass, Jana; Duncan, Jennifer; Nunn, Anthony J; Turner, Mark A; Lutsar, Irja (2016). Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates. *Paediatric drugs*, 18 (3), 221–230.10.1007/s40272_016_0173_5. Pantazis, Nikos; Touloumi, Giota; Meyer, Laurence; Olson, Ashley; Costagliola, Dominique; Kelleher, Anthony D; Lutsar, Irja; Chaix, Marie-Laure; Fisher, Martin; Moreno, Santiago; Porter, Kholoud; , (2016). The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. *AIDS (London, England)*, 30 (6), 879–888.10.1097/QAD.0000000000000991. Brauer, Age; Telling, Kaiidi; Laht, Mailis; Kalmus, Piret; Lutsar, Irja; Remm, Maido; Kisand, Veljo; Tenson, Tanel (2016). Plasmid with colistin resistance gene mcr_1 in ESBL-producing *Escherichia coli* strains isolated from pig slurry in Estonia. *Antimicrobial agents and chemotherapy*, 60 (11), 6933–36.10.1128/AAC.00443_16. Avi, Radko; Pauskar, Merit; Karki, Tõnis; Kallas, Eveli; Jõgeda, Ene_Ly; Margus, Tõnu; Huik, Kristi; Lutsar, Irja (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV_1 CRF06_cpx in Estonia. *Journal of Medical Virology*, 88 (3), 448–454.10.1002/jmv.24361. Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene_Ly; Sunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. *Viral immunology*, 0–0.vim.2016.0057. Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene_Ly; Sunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). Differences in T cell distribution and CCR5 expression in HIV_positive and HIV_exposed seronegative persons who inject drugs. *Medical microbiology and immunology*, 205 (3), 231–239.10.1007/s00430_015_0444_8. Jõgeda, Ene_Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi (2016). Human T_lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. *Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases*, 43, 83–85.10.1016/j.meegid.2016.05.022. Padari, Helgi; Oselin, Kersti; Tasa, Tõnis; Metsvaht, Tuuli; Lõivukene, Krista; Lutsar, Irja (2016). Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? *BMC Pediatrics*, 16 (1), 206–206.10.1186/s12887_016_0753_0. Laisaar, K.T.; Raag, M.; Lutsar, I.; Uusküla, A. (2016). People living with HIV in Estonia: engagement in HIV care in 2013. *Eurosurveillance*, 21 (43), x–x.10.2807/1560_7917.ES.2016.21.43.30380. Soeorg, H.; Metsvaht, T.; Eelmäe, I.; Treumuth, S.; Merila, M.; Ilmoja, ML.; Lutsar, I. (2016). High prevalence of mecA positive coagulase_negative staphylococci (MR_CO NS) in breast milk (BM) of mothers of preterm neonates. The 34th Annual Meeting of the ESPID, May 10_14, 2016, Brighton, UK. European Society for Paediatric Infectious Diseases,. 2015 Jõgi, P.; Oona, M.; Toompere, K.; Lutsar, I. (2015). Estimated and reported incidence of pertussis in Estonian adults: A seroepidemiological study. *Vaccine*, 33 (38), 4756–4761.10.1016/j.vaccine.2015.08.007. Soodla, P.; Rajasaar, H.; Avi, R.; Zilmer, K.; Kink, K.; Novikova, L.; Huik, K.; Maimets, M.; Lutsar, I. (2015). Design and structure of the Estonian HIV Cohort Study (E_HIV). *Infectious Diseases*, 47 (11), 768–765.10.3109/23744235.2015.1061203. Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari_Liis; Lutsar, Irja (2015). Gut colonization by aerobic microorganisms is associated with route and type of nutrition in premature neonates. *Nutrition Research*, 35 (6), 496–503.10.1016/j.nutres.2015.04.006. Metsvaht, Tuuli; Nellis, Georgi; Varendi, Heili; Nunn, Anthony; Graham, Susan; Rieutord, Andre; Storme, Thomas; McElnay, James; Mulla, Hussain; Turner, Mark; Lutsar, Irja (2015). High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination. *BMC Pediatrics*, 15 (41), 1–10.10.1186/s12887_015_0359_y. Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda, E..L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms_592 and_1082 to the HIV, HBV and HCV serostatus among intravenous drug users. *Infection, genetics and evolution*, 30, 175–180.10.1016/j.meegid.2014.12.023. Mulla, Hussain; Yakkundi, Shirish; McElnay, James; Lutsar, Irja; Metsvaht, Tuuli; Varendi, Heili; Nellis, Georgi; Nunn, Anthony; Duncan, Jennifer; Pandya, Hitesh; Turner, Mark (2015). An observational study of blood concentrations and kinetics of methyl_ and propyl_parabens in neonates. *Pharmaceutical research*, 32 (3), 1084–1093.10.1007/s11095_014_1520_2. Rhee, S..Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila_Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M..L. ... Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV_1 Drug Resistance: An Individual_Patient_ and Sequence_Level Meta_Analysis. *PLOS Medicine*, 12 (4), e1001810.10.1371/journal.pmed.1001810. Parm, Ü.; Niitvägi, E.; Beljaev, K.; Aro, T.; Aotäht, E.; Raska, K.; Epstein, J.; Oona, M.; Lutsar, I. (2015). Puukõrreliioos Saaremaal. *Eesti Arst*, 94 (4), 203–210. Taba, P.; Lutsar, I. (2015). Chronic infectious inflammatory diseases of the central nervous system. In: Deisenhammer, F.; Sellebjerg, F.; Teunissen, C.E.; Tumani, H. (Ed.). *Cerebrospinal Fluid in Clinical Neurology* (211–245).. Springer.10.1007/978_3_319_01225_4_15. Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I. (2015). Molecular epidemiology of *Staphylococcus epidermidis* colonizing gastrointestinal tract of neonates hospitalized to intensive care unit. The 25th European Congress of Clinical Microbiology and Infectious Diseases, April 25_28, 2015, Copenhagen, Denmark.. Soeorg H, Metsvaht T, Eelmäe I, Merila M, Ilmoja ML, Lutsar I. (2015). Colonization of gastrointestinal tract (GIT) of preterm neonates with *Staphylococcus epidermidis* (SE) present in mother's own unpasteurized breast milk (BM). The 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases, May 12_16, 2015, Leipzig, Germany.. Nellis, Georgi; Varendi, Heili; Lutsar, Irja; Metsvaht, Tuuli (2015). Kõik Euroopa vastündinutele manustatavad teadaolevate kõrvaltoimetega abained ei ole hädavajalikud. *Eesti Arst: TÜ Arstiteaduskonna aastapäeva teaduskonverents, Tartu, Eesti, 2015. 12.* Nellis, Georgi; Lutsar, Irja; Varendi, Heili; Turner, Mark; Metsvaht, Tuuli (2015). Potentially harmful excipients in medicines prescribed in neonatal intensive care units (NICUs) – product substitution as a way forward. *J Pediatr Neonat Individual Med: 1st*

Congress of joint European Neonatal Societies (jENS), Budapest, Hungary, 2015. 10.7363/040212. Rööp, Tiiu; Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari_Liis; Lutsar, Irja; Mändar, Reet. (2015). Collection of antibiotic resistant microbes of neonatal origin in the Human Microbiota Biobank (HUMB) at the Department of Microbiology, University of Tartu. XXXIV ECCO meeting: European Culture Collections as tools in research and biotechnology, Institut Pasteur (CRBIP) in Paris, France, 27_29 May, 2015. Jögi, P.; Oona, M.; Lutsar, I. (2015). Pertussis epidemiology and clinical characteristics in Estonia. 3rd Baltic Paediatric Congress, Riga, Latvia, 19_21 August, 2015. Jögi, P.; Oona, M.; Toompere, K.; Lutsar, I. (2015). Estimated versus reported incidence of pertussis in Estonian adults. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 25_28, 2015. Jögi, P.; Oona, M.; Epstein, J.; Lutsar, I. (2015). Epidemiology of pertussis in Estonian infants over the last 25 years. 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases. Leipzig, Germany, May 12_16, 2015. Kogermann, Karin; Putrins, Marta; Lippus, Markus; Smidt, Imbi; Truusalu, Kai; Lutsar, Irja; Tenson, Tanel (2015). Development of *Escherichia coli* systemic infection model for monitoring persisters and antibiotic susceptibility. In: .ECCMID 2015 Copenhagen, Denmark, 25_28 April 2015. ECCMID 2015 Copenhagen, Denmark, 25_28 April 2015. Kogermann, Karin; Putrins, Marta; Lippus, Markus; Smidt, Imbi; Truusalu, Kai; Lutsar, Irja; Tenson, Tanel (2015). Bacterial phenotypic heterogeneity – single_cell level methods to study antimicrobial susceptibility during infection. In: .6th BBBB Conference on Pharmaceutical Sciences, 10_12.09.2015, Helsinki, Finland. 2014 Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rütel, K.; Talu, A.; Abel_Ollo, K.; Uusküla, A.; Carrillo, A.Q.; He, W.; Ahuja, S.K.; Lutsar, I. (2014). Association between HIV_1 tropism and CCR5 human haplotype E in a Caucasian population. *J AIDS Journal of Acquired Immune Deficiency Syndromes*, 66 (3), 239–244.10.1097/QAI.000000000000127. Lutsar, I.; Chazallon, C.; Carducci, F.I.; Trafojer, U.; Abdelkader, B.; de Cabre, V.M.; Esposito, S.; Giaquinto, C.; Heath, P.T.; Ilmoja, M.L.; Katraglou, A.; Lascoux, C.; Metsvaht, T.; Mitsiakos, G.; Netzer, E.; Pugni, L.; Roilides, E.; Saidi, Y.; Sarafidis, K.; Sharland, M. ... Aboulker, J.P. (2014). Current management of late onset neonatal bacterial sepsis in five European countries. *European Journal of Pediatrics*, 173 (8), 997–1004.10.1007/s00431_014_2279_5. Mitt, P.; Metsvaht, T.; Adamson, V.; Telling, K.; Naaber, P.; Lutsar, I.; Maimets, M. (2014). Five_year prospective surveillance of nosocomial bloodstream infections in an Estonian paediatric intensive care unit. *Journal of Hospital Infection*, 86 (2), 95–99.10.1016/j.jhin.2013.11.002. Turner, M.A.; Duncan, J.C.; Shah, U.; Metsvaht, T.; Varendi, H.; Nellis, G.; Lutsar, I.; Yakkundi, S.; McElroy, J.C.; Pandya, H.; Mulla, H.; Vaconsin, P.; Storme, T.; Rieutord, A.; Nunn, A.J. (2014). Risk assessment of neonatal excipient exposure: Lessons from food safety and other areas. *Advanced Drug Delivery Reviews*, 73, 89–101.10.1016/j.addr.2013.11.003. Avi, R.; Huik, K.; Pauskar, M.; Ustina, V.; Karki, T.; Kallas, E.; Jögeda, E.L.; Krispin, T.; Lutsar, I. (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpxinfected patients in Estonia in 2010. *Aids Research and Human Retroviruses*, 30 (3), 278–283.10.1089/aid.2012.0357. Kõljalg, S.; Telling, K.; Huik, K.; Murruste, M.; Saarevet, V.; Pauskar, M.; Lutsar, I. (2014). First report of *Wohlfahrtiimonas chitiniclastica* from soft tissue and bone infection at an unusually high northern latitude. *Folia Microbiologica*, 60 (2), 155–158.10.1007/s12223_014_0355_x. Simmons, R.; Lutsar, I.; Malyuta, R.; Rosińska, M.; Porter, K. (2014). Using incidence assays within the context of the recent infections testing algorithm. *AIDS*, 28 (14), 2167–2167.10.1097/QAD.0000000000000367. Nellis, G.; Lutsar, I.; Varendi, H.; Toompere, K.; Turner, M.A.; Duncan, J.; Metsvaht, T. (2014). Comparison of two alternative study designs in assessment of medicines utilisation in neonates. *BMC Medical Research Methodology*, 14, 89–94.10.1186/1471_2288_14_89. Lutsar, I.; Telling, K.; Metsvaht, T. (2014). Treatment option for sepsis in children in the era of antibiotic resistance. *Expert Review of Anti_infective Therapy*, 12 (10), 1237–1252.10.1586/14787210.2014.956093. Jögi, P.; Oona, M.; Toompere, K.; Leedo, S.; Epstein, J.; Lutsar, I. (2014). Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia. *Vaccine*, 32 (41), 5311–5315.0.1016/j.vaccine.2014.07.066. Drell, Tiina; Lutsar, Irja; Štšepetova, Jelena; Parm, Ülle; Metsvaht, Tuuli; Ilmoja, Mari_Liis; Simm, Jaak; Sepp, Epp. (2014). The development of gut microbiota in critically ill extremely low birth weight infants assessed with 16S rRNA gene based sequencing. *Gut Microbes*, 5, 1–7. Toome, Liis; Plado, Silvi; Ringmets, Inge; Vals, Mari_Anne; Varendi, Heili; Lutsar, Irja (2014). Respiratory infections in very low gestational age infants: a population_based cohort study in Estonia. *Journal of Pediatric and Neonatal Individualized Medicine*, 3 (1), 1–10.10.7363/030115. Soeorg H, Huik K, Parm Ü, Ilmoja ML, Metsvaht T, Lutsar I. (2014). Vancomycin_heteroresistance in *Staphylococcus epidermidis* colonizing neonates in neonatal intensive care units. The 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases, May 6_10, 2014, Dublin, Ireland.. Jögi, P.; Oona, M.; Toompere, K.; Epstein, J.; Lutsar, I. (2014). Does the number of boosters and the diagnostic method influence the notification of pertussis? 32th Annual Meeting of the European Society for Paediatric Infectious Diseases. Dublin, Ireland, May 6_10. 2013 Oeser, C; Lutsar, I; Metsvaht, T; Turner, M.A; Heath, P.T; Sharland, M (2013). Clinical trials in neonatal sepsis. *The Journal of Antimicrobial Chemotherapy*, 68 (12), 2733–2745.10.1093/jac/dkt297. Garazzino, S; Lutsar, I; Bertaina, C; Tovo, P.A; Sharland, M (2013). New antibiotics for paediatric use: A review of a decade of regulatory trials submitted to the European Medicines Agency from 2000 Why aren't we doing better? *International Journal of Antimicrobial Agents*, 42 (2), 99–118.10.1016/j.ijantimicag.2013.05.001. Soeorg, H.; Huik, K.; Parm, U.; Ilmoja, M.; Metelskaja, N.; Metsvaht, T.; Lutsar, I. (2013). Genetic Relatedness of Coagulase_Negative Staphylococci from Gastrointestinal Tract and Blood of Preterm Neonates with Late_Onset Sepsis. *The Pediatric Infectious Disease Journal*, 32 (4), 389–393.10.1097/INF.0b013e3182791abd. Quinlivan, M.; Sengupta, N.; Papaevangelou, V.; Sauerbrei, A.; Grillner, L.; Rousseva, R.; Hague, R.; Lutsar, I.; Jögi, P.; Leca, A.; Grytchol, R.; Alain, S.; Breuer, J. (2013). Use of oral fluid to examine the molecular epidemiology of varicella zoster virus in the United Kingdom and continental Europe. *The Journal of Infectious Diseases*, 207 (4), 588–593.10.1093/infdis/jis649. Turner, Mark; Duncan, Jennifer; Shah, Utpal; Metsvaht, Tuuli; Varendi, Heili, Nellis, Georgi; Lutsar, Irja; Vaconsin, Pascal; Storme, Thomas; Rieutord, Andre; Nunn, Anthony (2013). European Study of Neonatal Exposure to Excipients: An update. *International Journal of Pharmaceutics*, 457 (1), 357–358.10.1016/j.ijpharm.2013.08.078. Lodi, S; del Amo, J; d'Arminio Monforte, A; Abgrall, S; Sabin, C; Morrison, C; Furrer, H; Muga, R; Porter, K; Girardi, E (2013). Risk of tuberculosis following HIV seroconversion in high_income countries. *Thorax*, 68 (3), 207–213.10.1136/thoraxjnl_2012_201740. Touloumi, G; Pantazis, N; Pillay, D; Paraskevis, D; Chaix, M.L; Bucher, H.C; Kucherer, C; Zangerle, R; Kran, A.M; Porter, K (2013). Impact of HIV_1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. *Clinical Infectious Diseases*, 56 (6), 888–897.10.1093/cid/cis1000. van der Helm, J; Geskus, R; Sabin, C; Meyer, L; Del Amo, J; Chene, G; Dorrucci, M; Muga, R; Porter, K; Prins, M (2013). Effect of HCV infection on cause_specific mortality after HIV seroconversion, before and after. *Gastroenterology*, 144 (4), 751–760.10.1053/j.gastro.2012.12.026. Rosinska, M; Marzec_Bogustawska, A; Janiec, J; Smolen_Dzirba, J; Wasik, T; Gniewosz, J; Zalewska, M; Murphy, G; McKinney, E; Porter, K (2013). High percentage of recent HIV infection among HIV_positive individuals newly diagnosed at voluntary counseling and testing sites in Poland. *Aids Research and Human Retroviruses*, 29 (5), 805–813.10.1089/aid.2012.0314. Madec, Y; Boufassa, F; Porter, K; Prins, M; Sabin, C; d'Arminio Monforte, A; Amornkul, P; Bartmeyer, B; Sannes, M; Venet, A; Lambotte, O; Meyer, L (2013). Natural history of HIV_control since seroconversion. *AIDS*, 27 (15), 2451–2460.10.1097/01.aids.0000431945.72365.01. Lodi, S; Fisher, M; Phillips, A; De Luca, A; Ghosn, J; Malyuta, R; Zangerle, R; Moreno, S; Vanhems, P; Boufassa, F; Guiguet, M; Porter, K (2013). Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. *PLoS ONE*, 8 (11), e78642.10.1371/journal.pone.0078642. Versporten, A.; Sharland, M.; Bielicki, J.; Drapier, N.; Vankerckhoven, V.; Goossens, H.; ARPEC, Project Group Members (incl. Lutsar I). (2013). The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web_based point prevalence survey in 73 hospitals worldwide. *The Pediatric Infectious Disease Journal*, 32 (6), e242–e253.10.1097/INF.0b013e318286c612. Brilene, T.; Soeorg, H.; Kiis, M.; Sepp, E.; Kõljalg, S.; Lõivukene, K.; Jürna_Ellam, M.; Kalinina, J.; Štšepetova, J.; Metsvaht, T.; Lutsar, I. (2013). In vitro synergy of oxacillin and gentamicin against coagulase_negative staphylococci from blood cultures of neonates with late_onset sepsis. *APMIS*, 121 (9), 859–864.10.1111/apm.12048. Huik, K.; Avi, R.; Pauskar, M.; Kallas, E.; Jögeda, E.L.; Karki, T.; Marsh, K.; Des Jarlais, D.; Uusküla, A.; Lutsar, I. (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. *Infection, genetics and evolution*, 20, 78–82.10.1016/j.meegid.2013.08.008. Huik, K.; Avi, R.; Carrillo, A.; Harper, N.; Pauskar, M.; Sadam, M.; Karki, T.; Krispin, T.; He, W.; Lutsar, I. (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. *PLoS ONE*, 8 (7), e70561.10.1371/journal.pone.0070561. Standing, J.F.; Tsolia, M.; Lutsar, I. (2013). Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children. *Infectious Disorders _ Drug Targets*, 13 (1), 6–14. Lass, J.; Odland, V.; Irs, A.; Lutsar, I. (2013). Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden. *SpringerPlus*, 2, 124–x.10.1186/2193_1801_2_124. Lill, M.; Kõks, S.; Soomets, U.;

Schalkwyk, L.C.; Fernandes, C.; Lutsar, I.; Taba, P. (2013). Peripheral blood RNA gene expression profiling in patients with bacterial meningitis. *Frontiers in Neuroscience*, 7, 33.10.3389/fnins.2013.00033. Turner, M.; Yakkundi, S.; Varendi, H.; Metsvaht, T.; Nellis, G.; Windrow, J.; Graham, S.; Mulla, H.; Pandya, H.; Tapscott, S.; Caldwell, N.; Duncan, J.; Lutsar, I.; McElnay, J. (2013). Methyl and propyl paraben concentrations in blood from preterm neonates exposed to clinically indicated medicines are lower than the concentrations of these anti-microbial excipients reported to affect cell physiology. 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (EDPPP), Salzburg, Austria, 04_07.06.2013. Nellis, G.; Metsvaht, T.; Lass, J.; Varendi, H.; Turner, M.; Lutsar, I. (2013). European Study of Neonatal Excipient Exposure (ESNEE): preliminary results of the point prevalence survey. 14th Biannual Congress of the European Society for Developmental Perinatal and Pediatric Pharmacology (EDPPP), Salzburg, Austria, 04_07.06.2013. 2012 Jarrin, I.; Pantazis, N.; Gill, M.J.; Geskus, R.; Perez_Hoyos, S.; Meyer, L.; Prins, M.; Touloumi, G.; Johnson, A.; Hamouda, O.; de Olalla, P.G.; Porter, K.; del Amo, J. (2012). Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. *Clinical Infectious Diseases*, 54 (1), 111–118.10.1093/cid/cir814. Pulcini, C.; Bush, K.; Craig, WA; Frimodt_Moller, N.; Grayson, ML; Mouton, JW; Turnidge, J; Harbarth, S; Gyssens, IC (2012). Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. *Clinical Infectious Diseases*, 54 (2), 268–274.10.1093/cid/cir838. Pantazis, N.; Morrison, C.; Amornkul, P.N.; Lewden, C.; Salata, RA; Minga, A; Chipato, T; Jaffe, H; Lakhii, S; Karita, E; Porter, K; Meyer, L; Touloumi, G (2012). Differences in HIV natural history among African and nonAfrican seroconverters in Europe and seroconverters in sub-Saharan Africa. *PLoS ONE*, 7 (3), e32369.10.1371/journal.pone.0032369. Zugna, D.; Geskus, R.B.; De Stavola, B.; Rosinska, M.; Bartmeyer, B.; Boufassa, F.; Chaix, M.L.; Babiker, A.; Porter, K. (2012). Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. *Antivir Ther* 17:1039_1048. *Antiviral Therapy*, 17 (6), 1039–1048.10.3851/IMP2312. Huang, X.; Lodi, S.; Fox, Z.; Li, W.; Phillips, A.; Porter, K.; Lutsar, I.; Kelleher, A.; Li, N.; Xu, X.; Wu, H.; Johnson, A.M. (2012). Rate of CD4 decline and HIV RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. *J AIDS Journal of Acquired Immune Deficiency Syndromes*, 62 (4), 441–446.10.1097/QAI.0b013e31827f5c9a. Lass, J.; Naelapää, K.; Shah, U.; Käär, R.; Varendi, H.; Turner, M.A.; Lutsar, I. (2012). Hospitalised neonates in Estonia commonly receive potentially harmful excipients. *BMC Pediatrics*, 12, 136.10.1186/1471_2431_12_136. Padari, H.; Metsvaht, T.; Kõrgvee, L.T.; Germovsek, E.; Ilmoja, M.L.; Kipper, K.; Herodes, K.; Standing, J.F.; Oselin, K.; Lutsar, I. (2012). Short versus Long Infusion of Meropenem in Very_Low_Birth_Weight Neonates. *Antimicrobial Agents and Chemotherapy*, 56 (9), 4760–4764.10.1128/AAC.00655_12. Esposito, S.; Cohen, R.; Domingo, J.D.; Pecurariu, O.F.; Greenberg, D.; Heininger, U.; Knuf, M.; Lutsar, I.; et al. (2012). Antibiotic Therapy for Pediatric Community_Acquired Pneumonia: Do We Know When, What and For How Long to Treat? *The Pediatric Infectious Disease Journal*, 31 (6), e78–e85.10.1097/INF.0b013e318255dc5b. Soeorg, H.; Huik, K.; Pauskar, M.; Mägi, D.; Pruedel, K.; Vainomäe, L.; Moosar, L.; Kirss, K.; Torm, S.; Närska, M.; Pütsepp, A.; Nurm, H.; Pruunsild, K.; Jänes, A.; Zilmer, K.; Lutsar, I. (2012). Group A rotavirus genotypes circulating prior to implementation of a National Immunization Program in Estonia. *Human Vaccines*, 8 (4), 465–469.10.4161/hv.19135. Tamme, Kadri; Minajeva, Ave.; Adamson, Vivika; Ristmägi, Kaarina; Pöder, Jaak; Lutsar, Irja (2012). Clinical Findings and Pathologic Changes Associated with Fatal Cases of 2009/2010 Pandemic Influenza A/H1N1 Viral Infection in Estonia. A Retrospective Study. *Medicina (Kaunas)*, 48 (1), 48–56. Jõgi, P.; Oona, M.; Tamm, E.; Lutsar, I. (2012). Läkakõha nüüdisaegne diagnostika. *Eesti Arst*, 91 (1), 19–25. Prükk, T.; Maimets, M.; lutsar, I. (2012). Lymefi tõve nüüdisaegne diagnostika ja ravi. *Eesti Arst*, 91 (2), 141–147. Lass, Jana; Metsvaht, Tuuli; Nellis, Georgi; Lutsar, Irja (2012). The comparability of different study methodologies for evaluating antibiotic consumption in neonatal intensive care units (NICU). *ESPID*. Nellis, Georgi; Varendi, Heili; Lass, Jana; Lutsar, Irja; Metsvaht, Tuuli. (2012). Antibiotic prescribing in European neonatal intensive care units: service evaluation study of the European study of neonatal exposure to excipients. *Eesti Arst: TÜ Arstiteaduskonna päev, okt.2012*. 11. (91). Nellis, Georgi; Varendi, Heili; Lass, Jana; Lutsar, Irja; Metsvaht, Tuuli. (2012). Potentially Harmful Excipients in Antibiotics Prescribed to European Neonates _ ESNEE Survey. *Acta Médica Portuguesa: 3rd International Congress of UENPS, 2012; Porto, nov 14_17*. 141. (25; 2). Varendi, Heili; Nellis, Georgi; Metsvaht, Tuuli; Lass, Jana; Lutsar, Irja. (2012). European Study of the Neonatal Exposure to Excipients: Results of the Survey, Enterally Administered Products. *Acta Médica Portuguesa : 3rd International Congress of UENPS 2012; Porto, nov 14_17*. Portugal, 141–142. (25; S2). 2011 Yakkundi, Shirish; McElnay, James; Millership, Jeff; Mulla, Hussain; Pandya, Hitesh; Shah, Utpal; Nunn, Tony; Rieutord, Andre; Storme, Thomas; Vasconsin, Pascal; Metsvaht, Tuuli; Varendi, Heili; Nellis, Georgi; Lutsar, Irja; Turner, Mark. (2011). Use of dried blood spots to study excipient kinetics in neonates. *Bioanalysis*, 3 (24), 2691–2693. Lutsar, I.; Trafojer, U.M.; Heath, P.T.; Metsvaht, T.; Standing, J.; Esposito, S.; de Cabre, V.M.; Oeser, C.; Aboulker, J.P. (2011). Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. *Trials*, 12, 215.10.1186/1745_6215_12_215. Metsvaht, T.; Ilmoja, M.L.; Parm, U.; Merila, M.; Maipuu, L.; Mürsepp, P.; Julge, K.; Sepp, E.; Lutsar, I. (2011). Ampicillin versus penicillin in the empiric therapy of ELBW neonates at risk of early onset sepsis. *Pediatrics International*, 5 (53), 873–880. Freire_Moran, L.; Aronsson, B.; Manz, C.; Gyssens, IC.; So, AD.; Monnet, DL.; Cars, O.; ECDC_EMA Working Group (incl. Lutsar, I.) (2011). Critical shortage of new antibiotics in development against multidrugresistant bacteria Time to react is now. *Drug Resistance Updates*, 14, 118–124. Parm, U.; Metsvaht, T.; Sepp, E.; Ilmoja, M.L.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2011). Mucosal surveillance cultures in predicting Gram_negative late_onset sepsis in neonatal intensive care units. *Journal of Hospital Infection*, 78 (4), 327–332.10.1016/j.jhin.2011.03.025. Lass, Jana; Käär, Ruth; Jõgi, Kaarin; Varendi, Heili; Metsvaht, Tuuli; Lutsar, Irja (2011). Drug utilisation pattern and off_label use of medicines in Estonian neonatal units. *European Journal of Clinical Pharmacology*, 12 (67), 1263_1271-1271.DOI10.1007/s00228_011_1072_x. Mussini, C.; Cossariva, A.; Sabin, C.; Babiker, A.; De Luca, A.; Bucher, H.C.; Fisher, M.; Rezza, G.; Porter, K.; Dorrucci, M (2011). Decline of CD4(+) T_cell count before start of therapy and immunological response to treatment in antiretroviral_naive individuals. *AIDS*, 25 (8), 1041–1049.10.1097/QAD.0b013e3283463ec5. van der Helm, J.J.; Prins, M.; del Amo, J.; Bucher, H.C.; Chene, G.; Dorrucci, M.; Gill, J.; Hamouda, O.; Sannes, M.; Porter, K.; Geskus, R.B (2011). The hepatitis C epidemic among HIV_positive MSM: incidence estimates from 1990 to 2007. *AIDS*, 25 (8), 1083–1091.10.1097/QAD.0b013e3283471cce. Jaffe, H.W.; De Stavola, B.L.; Carpenter, L.M.; Porter, K.; Cox, D.R (2011). Immune reconstitution and risk of Kaposi sarcoma and non_Hodgkin lymphoma in HIV_infected adults. *AIDS*, 25 (11), 1395–1403.10.1097/QAD.0b013e3283489c8b. Lutsar, Irja (2011). Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. *Archives of Internal Medicine*, 171 (17), 1560–1569.10.1001/archinternmed.2011.401. Parm, U.; Metsvaht, T.; Sepp, E.; Ilmoja, M.L.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2011). Risk factors associated with gut and nasopharyngeal colonization by common Gram_negative species and yeasts in neonatal intensive unit patients. *Early Human Development*, 87 (6), 391–399.10.1016/j.earlhumdev.2011.02.007. Lass, J.; Irs, A.; Pisarev, H.; Leinemann, T.; Lutsar, I. (2011). Off label use of prescription medicines in children in outpatient setting in Estonia is common. *Pharmacoeconomics and Drug Safety*, 20 (5), 474–481.10.1002/pds.2125. Heidmets, L.T.; Metsvaht, T.; Ilmoja, M.L.; Pisarev, H.; Oselin, K.; Lutsar, I. (2011). Blood Loss Related to Participation in Pharmacokinetic Study in Preterm Neonates. *Neonatology*, 100 (2), 111–115. Avi, R.; Huik, K.; Pauskar, M.; Ustina, V.; Karki, T.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2011). Emerging Transmitted Drug Resistance in Treatment Naive Human Immunodeficiency Virus _ 1 CRF06_cpx Infected Patients in Estonia. *Scandinavian Journal of Infectious Diseases*, 43 (2), 122–128. Knellwolf, A.L.; Bauzon, S.; Della Casa Alberighi, O.; Lutsar, I.; Bacsy, E.; Alfarez, D.; Panei, P. (2011). Framework conditions facilitating paediatric clinical research. *Italian Journal of Pediatrics*, 37, 12.10.1186/1824_7288_37_12. Mürsepp, P.; Kõivumägi, K.; Kumm, M.L.; Zilmer, K.; Lutsar, I. (2011). Tuulerõuged laste ja noorukite hospitaliseerimise põhjusena Eestis aastatel 2000–2005. *Eesti Arst*, 91 (1), 27–32. Lill, M.; Lutsar, I.; Taba, P. (2011). Community_acquired bacterial meningitis in Estonia 2008_2009. *EUROPEAN JOURNAL OF NEUROLOGY*, 18: 15th Congress of the European_Federation_of_NeurologicalSocieties (EFNS) Location: Budapest, HUNGARY Date: SEP 10_13, 2011. 476. (SI 2). Standing, J.; Morris, J.; Germovsek, E.; Lutsar, I.; Cortina_Borja, M. (2011). Methods for Optimising Neonatal Antimicrobial Use: Time_and Concentration_Dependent Agents. Page Conference, Athens 2011. 2010 Wolbers, M.; Babiker, A.; Sabin, C.; Young, J.; Dorrucci, M.; Chene, G.; Mussini, C.; Porter, K.; Bucher, H.C (2010). Pretreatment CD4 cell slope and progression to AIDS or death in HIV_infected patients initiating antiretroviral therapythe CASCADE collaboration: a collaboration of 23 cohort studies. *PLOS Medicine*, 7 (2), e1000239.10.1371/journal.pmed.1000239. Walsh, T.J.; Driscoll, T.; Milligan, P.A.; Wood, N.D.; Schlam, H.; Groll, A.H.; Jafri, H.; Arrieta, A.C.; Klein, N.J.; Lutsar, I. (2010). Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. *Antimicrobial Agents and*

Chemotherapy, 54 (10), 4116–4123.10.1128/AAC.00896_10. Parm, Ü.; Metsvaht, T.; Sepp, E.; Ilmoja, ML.; Pisarev, H.; Pauskar, M.; Lutsar, I. (2010). Impact of empiric antibiotic regimen on bowel colonization in neonates with suspected early onset sepsis. *European Journal of Clinical Microbiology & Infectious Diseases*, 29 (7), 807–816.10.1007/s10096_010_0931_1. Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2010). Characterization of Integrase Region Polymorphisms in HIV_1 CRF06_cpx Viruses in Treatment Naive Patients in Estonia. *Aids Research and Human Retroviruses*, 26 (10), 1109–1113.10.1089/aid.2010.0097. Lutsar, I.; Metsvaht, T. (2010). Understanding pharmacokinetic/pharmacodynamic in managing neonatal sepsis. *Current Opinion in Infectious Diseases*, 23 (3), 201–207. Metsvaht, T.; Ilmoja, ML.; Parm, Ü.; Maipuu, L.; Merila, M.; Lutsar, I. (2010). Comparison of ampicillin plus gentamicin vs. penicillin plus gentamicin in empiric treatment of neonates at risk of early onset sepsis. *Acta Paediatrica*, 99 (5), 665–672.10.1111/j.1651_2227.2010.01687.x. Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rütel, K.; Uusküla, A.; Talu, A.; Abel Olo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. *The Journal of Infectious Diseases*, 730–739. Lutsar, I.; Friedland, I. (2010). *Clinical Trials of Anti-Infective Agents in Paediatrics*. In: Rose, Klaus; van den Anker, John N. (Ed.). *Guide to Paediatric Drug Development (170–177)*. Basel, Switzerland: Karger.10.1159/000315588. Lill, M.; Kõks, S.; Soomets, U.; Schalkwyk, L.C.; Fernandes, C.; Lutsar, I.; Taba, P. (2010). Peripheral blood RNA gene expression profiling in the patients with community acquired bacterial meningitis. In: (x).20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 10 _ 13 April. 2009 Brown, AE.; Gifford, RJ.; Clewley, JP.; Kucherer, C.; Masquelier, B.; Porter, K.; Balotta, C.; Back, NK.; Jorgensen, LB.; de Mendoza, C.; Bhaskaran, K.; Gill, ON.; Johnson, AM.; Pillay, D.; CASCADE Collaboration including Lutsar, I. (2009). Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more rigorous epidemiological definitions. *The Journal of Infectious Diseases*, 199 (3), 427–431. Prymula, R.; Anca, I.; André, F.; Bakir, M.; Czajka, H.; Lutsar, I.; Mészner, Z.; Salman, N.; Simurka, P.; Usonis, V. (2009). Central European Vaccination Advisory Group (CEVAG) guidance statements on recommendations for the introduction of HPV vaccines. *European Journal of Pediatrics*, 168, 1031–1035. Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2009). Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus_1 CRF06_cpx in Treatment_Naive Patients in Estonia. *Journal of Medical Virology*, 81 (6), 953–958.10.1002/jmv.21482. Karlsson, MO.; Lutsar, I.; Milligan, PA. (2009). A population pharmacokinetic of voriconazole plasma concentration data from pediatric studies. *Antimicrobial Agents and Chemotherapy*, 53 (3), 935–944.10.1128/AAC.00751_08. Lutsar, I.; Anca, I.; Bakir, M.; Usonis, V.; Prymula, R.; Salman, N.; Grezsiowski, P.; Greenberg, M. (2009). Epidemiological characteristics of pertussis in Estonia, Lithuania, Romania, the Czech Republic, Poland and Turkey 1945 to 2005. *European Journal of Pediatrics*, 168, 407–415.10.1007/s00431_008_0754_6. Metsvaht, T.; Pisarev, H.; Ilmoja, ML.; Parm, Ü.; Maipuu, L.; Merila, M.; Muurseppe, P.; Lutsar, I. (2009). Clinical parameters predicting failure of empirical antibacterial therapy in early onset neonatal sepsis, identified by classification and regression tree analysis. *BMC Pediatrics*, 9, 72.10.1186/1471_2431_9_72. Lutsar, I.; Metsvaht, T.; Tamm, E. (2009). Meningokokiline infektsioon lastel ja täiskasvanutel. *Eesti Arst*, 88 (1), 28–40. Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Denks, K.; Krispin, T.; Ustina, V.; Rütel, K.; Uusküla, A.; Murphy, G.; Lutsar, I. (2009). Performance of the BED_CIEA in population infected with HIV1 recombinant viruses CRF06cpx and CRF06A. *Clinical Microbiology and Infection: 19th European Congress of Clinical Microbiology and Infectious Diseases Helsinki, Finland, 16 _ 19 May 2009*. Lutsar Irja, Lass Jana (2009). Ravimite kasutamise lastel. *Lege Artis*, 5, 42–45. 2008 Jarrin, I.; Geskus, R.; Bhaskaran, K.; Prins, M.; Perez_Hoyos, S.; Muga, R.; Hernández_Aguado, I.; Meyer, L.; Porter, K.; del Amo, J.; Group author CASCADE Collaboration, (incl. I.Lutsar). (2008). Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. *American Journal of Epidemiology*, 168 (5), 532–540.10.1093/aje/kwn179. Bhaskaran, K.; Hamouda, O.; Sannes, M.; Bonfassa, F.; Johnson, A.M.; Lambert, P.C.; Porter, K.; CASCADE, Collaboration (2008). Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. *JAMA : the journal of the American Medical Association*, 300 (1), 51–59. Touloumi, G.; Pantazis, N.; Stirnadel, HA.; Walker, AS.; Boufassa, F.; Vanhems, P.; Porter, K.; Cascade including Lutsar, I. (2008). Rates and determinants of virologic and immunologic response to HAART resumption after treatment interruption in HIV_1 clinical practice. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 49 (5), 492–498. Pantazis, N.; Touloumi, G.; Vanhems, P.; Gill, J.; Buchere, HC.; Porter, K.; CASCADE Collaboration (incl. Lutsar, I.) (2008). The effect of antiretroviral treatment of different durations in primary HIV infection. *AIDS*, 22 (18), 2441–2450.10.1097/QAD.0b013e328319ea4e. Meriste, S.; Jacquet, J._M.; Willems, P.; Lutsar, I. (2008). Immunologic response to Hib tetanus toxoid conjugated vaccine coadministered with DTPa either mixed or in two separate injections in toddlers not primed with Hib vaccine. *Human Vaccines*, 4 (1), 31–35. Troke, P.; Aguirrebengoa, K.; Arteaga, C.; Ellis, D.; Heath, C.; Lutsar, I.; Rovira, M.; Nguyen, Q.; Slavina, M.; Chen, S. (2008). Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients. *Antimicrobial Agents and Chemotherapy*, 52 (5), 1743–1750. Uudelepp, ML.; Tamm, E.; Torm, S.; Urbsoo, K.; Pruunsild, K.; Part, R.; Lutsar, I. (2008). Bacterial meningitis in children in Estonia in 1980_1989 and 1998_2007. *17th ESPID; Graz, Austria; 13_17 May 2008*. Merila, M.; Metsvaht, T.; Parm, Ü.; Maipuu, L.; Muurseppe, P.; Lutsar, I. (2008). Maternal risk_factors of need for early change of empirical antibacterial treatment in neonates with high risk of sepsis. In: .26th ESPID; Graz, Austria; 13_17 May 2008. Eimra, K.; Parm, Ü.; Metsvaht, T.; Ilmoja, ML.; Lutsar, I. (2008). Genotypic Relatedness of *Candida* spp. in Two NICU_s in Estonia. 26. European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 19_22 Apr 2008. Parm, Ü.; Sepp, E.; Metsvaht, T.; Ilmoja, ML.; Pruunsild, K.; Maipuu, L.; Kõljalg, S.; Makoid, E.; Lutsar, I. (2008). The association between mucosal colonisation with opportunistic pathogens and blood stream infections in the two NICUs in Estonia. 26. European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19_22 Apr 2008. Metsvaht, T.; Ilmoja, M._L.; Parm, Ü.; Merila, M.; Maipuu, L.; Sepp, E.; Muurseppe, P.; Lutsar, I. (2008). Management of Early Onset Neonatal Sepsis (EOS): comparative study of ampicillin (AMP) vs penicillin (PEN) in combination with gentamicin (GEN). International Conference of Antimicrobial Agents and Chemotherapy; Washington; 24_28 Oct 2008. Truusalu, K.; Kõljalg, S.; Parm, Ü.; Sepp, E.; Metsvaht, T.; Naaber, P.; Löivukene, K.; Lutsar, I. (2008). Staphylococcal Infection and Colonization of Pediatric Intensive Care Unit Patients: MRSA versus MRSE. Abstract book: Emerging Technologies of Medical Importance for the Diagnosis of Infectious Diseases and the Detection of Pathogenic Microbes. 1 st International ASM Conference in Beijing, April 6_10, 2008. 44. Mitt, P.; Adamson, V.; Truusalu, K.; Parm, Ü.; Kõljalg, S.; Sepp, E.; Löivukene, K.; Lutsar, I.; Maimets, M. (2008). An outbreak of methicillin_resistant *Staphylococcus aureus* (spa type t008) in the paediatric intensive care unit of a university hospital, Tartu. *Clinical Microbiology and Infection*, 14: 18th European Congress of Clinical Microbiology and Infectious Diseases. Abstract number: P1439. (S7). Huik, K.; Avi, R.; Sadam, M.; Karki, T.; Albert, J.; Lutsar, I. (2008). Drug Resistance Mutations in HIV_1 CRF06_cpx Viruses Isolated from Treatment Naive and Experienced Patients. *European Journal of Medical Research: 19th European Students' Conference*; Berlin; 28 September _ 3 October 2008. Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Drug Resistance Mutations and Genetic Barrier for Drug Resistance Development in Estonian HIV_1 CRF06_cpx Integrase Sequences. 14th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology; Cape Town, South Africa; 1_5 September 2008. Avi, R.; Huik, K.; Sadam, M.; Karki, T.; Krispin, T.; Paap, P.; Ainsalu, K.; Schmidt, J.; Nikitina, N.; Lutsar, I. (2008). Natural polymorphisms associated with integrase inhibitor drug resistance in Estonian HIV_1 CRF06_cpx strains. 18th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 19.04_22.04.2008. Sadam, M.; Karki, T.; Huik, K.; Avi, R.; Rütel, K.; Uusküla, A.; Lutsar, I. (2008). CCL3L1 Variable Gene Copy Number Influence on the Susceptibility to HIV_1/AIDS Among Estonian Intravenous Drug User. The 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 03.02_06.02.2008. 2007 Tamm, E.; Naaber, P.; Maimets, M.; Oona, M.; Kõljalg, S.; Lutsar, I. (2007). Antimicrobial susceptibility and serogroup/serotype distribution of nasopharyngeal isolates of *Streptococcus pneumoniae* in healthy Estonian children in 1999_2003. *Clinical Microbiology and Infection*, 13 (8), 824–826.10.1111/j.1469_0691.2007.01743.x. Metsvaht, T.; Oselin, K.; Ilmoja, M.; Anier, K.; Lutsar, I. (2007). Pharmacokinetics of penicillin G in very_lowbirth_weight neonates. *Antimicrobial Agents and Chemotherapy*, 51 (6), 1995–2000. Sergejev, M.; Lutsar, I. (2007). Gripivastased ravimid. *Eesti Arst*, 86 (2), 82–84. Denks, K.; Huik, K.; Avi, R.; Sadam, M.; Krispin, T.; Lutsar, I. (2007). GB virus C infection among HIVpositive patients in Estonia. *International Journal of Antimicrobial Agents*, 29 (3), S155–S155. Avi, R.; Huik, K.; Karki, T.; Sadam, M.; Paap, P.; Smidt, J.; Ainsalu, K.; Krispin, T.; Lutsar, I. (2007). The coexistence of secondary PR mutations M36I, K20I and L63H predominates in CRF06_cpx and its next generation recombinant viruses circulating in Estonian treatment naive patients. *INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS*, 29. S549–S549. Parm, Ü., Sepp, E., Metsvaht, T., Ilmoja, M.L., Lutsar, I. (2007).

Oportunistlike mikroobide esinemine intensiivravi osakonnas viibivatel vastsündinutel. Eesti Arst, 86: Õppejõudude, teadurite, doktorantide, magistrantide ja üliõpilaste teaduskonverents 18. oktoobril 2007 TÜ Biomedikumis. Eesti Arst, 673. (9). Lutsar, I.; Mikelsaar, M.; Karki, T. (2007). Meditsiiniline mikrobioloogia II. Tartu: Tartu Ülikooli Kirjastus. 2006 Meriste, S.; Lutsar, I.; Tamm, E.; Willems, P. (2006). Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. *Scandinavian Journal of Infectious Diseases*, 38 (5), 350–356. Meriste, S.; Oona, M.; Tamm, E.; Lutsar, I. (2006). Immuniseerimisega välditavate nakkushaiguste levik ja preventsiion Euroopas ja Eestis. Eesti Arst, 85 (2), 107–126. Mikelsaar, M.; Karki, T.; Lutsar, I.; Mändar, R. (2006). Meditsiiniline mikrobioloogia I. Tartu: Tartu Ülikooli Kirjastus. 2005 Mouas, H.; Lutsar, I.; Dupont, B.; Fain, O.; Herbrecht, R.; Lescure, F.; Lortholary, O. (2005). Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. *Clinical Infectious Diseases*, 40 (8), 1141–1147. Usonis, V.; Meriste, S.; Bakasenas, V.; Lutsar, I.; Collard, F.; Stoffeld, A.; Tornieporth, N. (2005). Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles_mumps_rubella or a diphtheria_tetanus_acellular pertussis_inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12_18 months. *Vaccine*, 23 (20), 2602–2606. Schwartz, S.; Ruhnke, M.; Ribaud, P.; Corey, L.; Driscoll, T.; Cornely, O.A.; Schuler, U.; Lutsar, I.; Troke, P.; Thiel, E. (2005). Improved outcome in central nervous system aspergillosis, using voriconazole treatment. *Blood*, 106 (8), 2641–2645. Lutsar, I. (2005). HI viirusinfektsioon kui globaalne probleem. Eesti Arst, 4, 238–243. Lutsar, I.; Tamm, E.; Metsvaht, T.; Roos, R. (2005). Antimikroobsete ravimite manustamine lastele. Tallinn: Medicina. Roos, R.; Adamson, V.; Lutsar, I.; Metsvaht, T. (2005). Antibiootikumide (AB) tarbimise ja koormuse hindamine TÜ Kliinikumi lasteintensiivravi osakonnas: modifitseeritud DDD meetoodika. Eesti Arst, 84. 679–679. (9). Metsvaht, T.; Padari, H.; Lutsar, I. (2005). Ampitsilliin_gentamüsiin versus penitsilliin_gentamüsiin varase empiirilise antibakteriaalse ravi valikuna vastsündinutel. Eesti Arst, 84. Eesti Arst, 672–673. (9). 2004 Walsh, T.J.; Karlsson, M.O.; Driscoll, T.; Arguedas, A.G.; Adamson, P.; Saez_Llorens, X.; Vora, A.J.; Arrieta, A.C.; Blumer, J.; Lutsar, I.; Milligan, P.; Wood, N. (2004). Pharmacokinetics and safety of intravenous voriconazole in children after single and multiple dose administration. *Antimicrobial Agents and Chemotherapy*, 48 (6), 2166–2172. Steinbach, W.J.; Benjamin, D.K.; Kontoyiannis, D.P.; Perfect, J.R.; Lutsar, I.; Marr, K.A.; Lionakis, M.S.; Torres, H.A.; Jafri, H.; Walsh, T.J. (2004). Infections due to *Aspergillus terreus*: multicenter retrospective analysis of 83 cases. *Clinical Infectious Diseases*, 39, 192–198. 2003 Lutsar, I.; Roffey, S.; Troke, P. (2003). Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. *Clinical Infectious Diseases*, 37 (5), 728–732. Lutsar, I.; Hodges, MR.; Tomaszewski, K.; Troke, PF.; Wood, ND. (2003). Safety of voriconazole and dose individualisation. *Clinical Infectious Diseases*, 36 (8), 1087–1088. Lutsar, I.; Friedland, IR.; Wubbel, L.; Ahmed, A.; Trujillo, M.; McCoig, CC.; Jafri, HH.; McCracken, GH.Jr. (2003). Factors influencing the anti_inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. *Journal of Antimicrobial Chemotherapy*, 52 (4), 651–655. Perfect, JR.; Marr, KA.; Walsh, TJ.; Greenberg, RN.; Dupont, B.; De La Torre_Cisneros, J.; Just_Nübling, G.; Schlamm, H.; Lutsar, I.; Espinel_Ingraff, A.; Johnson, E. (2003). Voriconazole treatment for less common, emerging or refractory fungal infections. *Clinical Infectious Diseases*, 36 (9), 1122–1131. Tamm, E.; Kõljalg, S.; Lutsar, I.; Maimets, M.; Naaber, P. (2003). Pneumokokkinfektsioon lapseas. Eesti Arst, 82 (7), 464–471. 2002 Walsh, TJ.; Lutsar, I.; Driscoll, T.; Dupont, B.; Roden, M.; Ghahramani, P.; Hodges, M.; Groll, AH.; Perfect, JR. (2002). Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. *The Pediatric Infectious Disease Journal*, 21 (3), 240–248. 2000 Lutsar, I.; Friedland, IR. (2000). Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. *Clinical Pharmacokinetics*, 39 (5), 335–343. Ng, W.; Olsen, K.; Lutsar, I.; Wubbel, L.; Ghaffar, F.; Jafri, H.; McCracken, GH.; Friedland, I. (2000). Buffy coat PCR for diagnosis of experimental pneumococcal pneumonia. *APMIS*, 108 (11), 729–733. 1999 Meriste, S.; Tamm, E.; Willems, P.; Lutsar, I. (1999). Safety and immunogenicity of combined DTPa_IPV for primary and booster vaccination. *Scandinavian Journal of Infectious Diseases*, 31 (6), 587–591. Ahmed, A.; Jafri, H.; Lutsar, I.; McCoig, CC.; Trujillo, M.; Wubbel, L.; Shelton, S.; McCracken, GH. (1999). Pharmacodynamics of vancomycin for the treatment of experimental penicillin_ and cephalosporin_resistant pneumococcal meningitis. *Antimicrobial Agents and Chemotherapy*, 43 (4), 876–881. Lutsar, I.; Friedland, IR.; Jafri, HS.; Wubbel, L.; Ng, W.; Ghaffar, F.; McCracken, GH.Jr. (1999). Efficacy of gatifloxacin in experimental *Escherichia coli* meningitis. *Antimicrobial Agents and Chemotherapy*, 43 (7), 1805–1807. McCoig, CC.; Friedland, IR.; Lutsar, I.; Jafri, HS.; Wubbel, L.; Olsen, K.; Shelton, S.; McCracken, GH.Jr. (1999). Pharmacodynamics and bactericidal activity of trovafloxacin in cerebrospinal fluid in experimental cephalosporin_resistant pneumococcal meningitis. *Journal of Antimicrobial Chemotherapy*, 43 (5), 683–688. Ng, W.; Lutsar, I.; Wubbel, L.; Jafri, H.; Ghaffar, F.; McCracken, GH.Jr.; Friedland, IR. (1999). Pharmacodynamics of trovafloxacin in the cephalosporin_resistant pneumococcal pneumonia in immunocompetent mice. *Journal of Antimicrobial Chemotherapy*, 43 (6), 811–816. 1998 Lutsar, I.; Friedland, I.; Wubbel, L.; McCoig, C.; Jafri, H.; Ghaffar, F.; McCracken, G. (1998). Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin_resistant pneumococcal meningitis. *Antimicrob Agents and Chemotherapy*, 42 (10), 2650–2655. Lutsar, I.; McCracken, GH.; Friedland, IR. (1998). Antibiotic pharmacodynamics in cerebrospinal fluid. *Clinical Infectious Diseases*, 27 (5), 1117–1127. Friedland, IR.; Lutsar, I. (1998). New Antibiotics. *Current Opinion in Pediatrics*, 10 (1), 41–45. 1997 Lutsar, I.; Ahmed, A.; Friedland, IR.; Trujillo, M.; Wubbel, L.; Olsen, K.; McCracken, GH. (1997). Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin_resistant pneumococcal meningitis. *Antimicrobial Agents and Chemotherapy*, 41 (11), 2414–2417. Lutsar, I.; Friedland, IR.; McCracken, GH.Jr. (1997). Pathogenesis of bacterial meningitis. *Annals Nestle*, 55, 92–102. 1996 Siigur, U.; Tamm, E.; Torm, S.; Lutsar, I.; Salminen, S. (1996). Effect of bacterial infection and administration of a probiotic on fecal short_chain fatty acids. *Microbial Ecology in Health and Disease*, 9 (6), 271–277. 1995 Lutsar, I.; Gontmacher, A.; Närska, M.; Rüütel, V.; Topman, M.; Ilves, P.; Siirde, T.; Beilmann, A. (1995). Five days of antibacterial therapy for bacterial meningitis in children. *Infection*, 23 (2), 113–118. Lutsar, I.; Siirde, T.; Soopold, T. (1995). Long term follow_up of Estonian children after bacterial meningitis. *The Pediatric Infectious Disease Journal*, 14 (7), 624–625. Sepp, E.; Tamm, E.; Torm, S.; Lutsar, I.; Mikelsaar, M.; Salminen, S. (1995). Impact of a lactobacillus probiotic on the faecal microflora in children with shigellosis. *Microecology and Therapy*, 23, 74–80. 1994 Lutsar, I.; Haldre, S.; Topman, M.; Talvik, T. (1994). Enzymatic changes in the cerebrospinal_fluid in patients with infections of the central_nervous_system. *Acta Paediatrica*, 83 (11), 1146–1150.

Projects

Current grants & projects Infection and immunocompromised host _ from mechanisms to translation into clinical practice Laste seeninfektsioonide rahvusvaheline võrgustik c4c (Conect for Children)

Memberships

European Society for Paediatric Infectious Diseases Estonian Society of Infectious Diseases Estonian Society for Paediatrics Fellowship award of the European Society for Paediatric Infectious Diseases in 1995 Editorial Board of The Pediatric Infectious Diseases Journal

Other Relevant Information

Administrative responsibilities 2012 _ ... Estonian Science Agency, Member of Evaluation Committee 2011 _ ... senat member of University of Tartu 2010 _ ... European Society for Paediatric Infectious Diseases _ board member 2007 _ ... EMEA, Pedaitric Committe, member 2005 _ ... EMEA, Scientific Advisory Group on antiinfectives 2006 _ 2012 Estonian Science Foundation, Expert Committee of Health Sciences, chair 2002 _ 2005 European Society for Pediatric Infectious Diseases, Member of scientific committee 1998 _ 1999 Estonian Infectious Diseases Society, president 1994 _ 1994 Congress of Estonian Pediatric Association, Tallinn _ member of organizing committee 1993 _ 1993 2nd International Meeting of Baltic Association of Child Neurology, Riga _ member of organizing committee 1993 _ 1993 International symposium Impact of the environment to children's health, Tartu _ secretary general 1992 _ 1994 Estonian Infectious Diseases Society, Board member 1991 _ 1991 1st International Meeting of Baltic Association of Child Neurology, Tartu _ secretary general 1990 _ 1995 Estonian Pediatric Association, Board member 1990 _ 1993 Baltic Association of Child Neurology, Board member 1989 _ 1989 Congress of Estonian Pediatric Association, Tallinn _ member of organizing committee Honours & Awards 2010, Irja Lutsar; Estonian Government Annual Award in Medical Sciences 2010, Yearly Award, Health _ Irja Lutsar; Infektsioonide käsitus omandatud immuunpuudulikkusega isikutel 1995, Irja Lutsar; European Society for Pediatric Infectious Diseases fellowship award 1994, Irja Lutsar; Estonian Government award in medical science, 1994 European Society for Pediatric Infectious Diseases fellowship award Field of research 3. Health, 3.7. Clinical Medicine (Infections in neonates, their pathogenesis and management. Infections of the central nervous system in children, their pathogenesis, treatment and long term outcome . Pharmacokinetic and pharmacodynamic properties of antiinfective agents in children . HIV infection, the importance of recombinant viruses in the disease process.) 3. Health, 3.7. Clinical Medicine, B510

Infections